Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma - Trial NCT06406634
Access comprehensive clinical trial information for NCT06406634 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Cancer Hospital and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hunan Cancer Hospital
Timeline & Enrollment
Phase 2
May 15, 2024
Apr 20, 2027
Primary Outcome
Objective Response Rate
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the
 effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial
 Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06406634
Non-Device Trial